Bio-Matrix Scientific Group Inc (BMSN) 0.0004 $BMSN
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.52 (+0.08), ICEL: 16.55 (+0.03), CYTX: 0.42 (+0.02), ATHX: 1.14 (-0.01)
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Cell Therapy Expert Dr. Amit Patel Joins Regen BioPharma Inc. Scientific Advisory Board
Marketwired - Wed Oct 15, 9:01AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the appointment of Dr. Amit Patel to the company's Scientific Advisory Board (SAB). Dr. Patel is Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and has been involved in over 17 FDA trials in the area of cellular therapy. Dr. Patel currently holds more than $7 million in research grants for basic and clinical research in the area of regenerative medicine.
Regen BioPharma Inc. Files IND Application With FDA for dCellVax Breast Cancer Immune Therapy
Marketwired - Wed Oct 08, 11:29AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the filing of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to initiate a clinical trial assessing safety and therapeutic effects of dCellVax in patients with metastatic breast cancer. dCellVax is an immunotherapeutic product that utilizes the patient's own immune cells to attack the tumor. Success of dCellVax in the proposed trial is anticipated to pave the way for expanded use of dCellVax in a variety of other tumors. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
Regen BioPharma Submits Experimental Protocol to FDA for HemaXellerate Aplastic Anemia Trial
Marketwire - Mon Oct 06, 1:54PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today submission of a proposed experimental protocol to the FDA as part of ongoing discussions regarding initiation of a 10 patient aplastic anemia clinical trial utilizing the company's personalized adipose stem cell based therapy, HemaXellerate. The protocol submission was the result of a telephonic meeting with FDA officials, in which the Agency permitted the Company to provide additional input on preclinical safety experiments that need to be conducted before the clinical trial is initiated.
Regen BioPharma Completes Preclinical Experiments for dCellVax Breast Cancer Immune Therapy
Marketwire - Wed Oct 01, 12:46PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today completion of its preclinical experiments supporting the use of dCellVax, a personalized breast cancer immunotherapy. Animal studies, which have been previously published in peer-reviewed journals (1, 2), demonstrated that dCellVax is effective at stimulating the immune system of animals to kill tumors. In order to apply these findings to humans, proof of concept in human cells was needed.
Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
Marketwire - Tue Sep 16, 10:44AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer.
Regen BioPharma Provides Update on HemaXellerate IND Progress After Conference Call With FDA
Marketwire - Wed Sep 10, 9:01AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the outcome of a telephonic meeting with the FDA regarding IND #15376 for use of HemaXellerate in the treatment of aplastic anemia. The subject of this meeting with FDA cell therapy experts was the Company's existing experimental data and the requirement for additional safety data with regard to the IND application.
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.52 (+0.08), ICEL: 16.55 (+0.03), CYTX: 0.42 (+0.02), ATHX: 1.14 (-0.01)
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Cell Therapy Expert Dr. Amit Patel Joins Regen BioPharma Inc. Scientific Advisory Board
Marketwired - Wed Oct 15, 9:01AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the appointment of Dr. Amit Patel to the company's Scientific Advisory Board (SAB). Dr. Patel is Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and has been involved in over 17 FDA trials in the area of cellular therapy. Dr. Patel currently holds more than $7 million in research grants for basic and clinical research in the area of regenerative medicine.
Regen BioPharma Inc. Files IND Application With FDA for dCellVax Breast Cancer Immune Therapy
Marketwired - Wed Oct 08, 11:29AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the filing of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to initiate a clinical trial assessing safety and therapeutic effects of dCellVax in patients with metastatic breast cancer. dCellVax is an immunotherapeutic product that utilizes the patient's own immune cells to attack the tumor. Success of dCellVax in the proposed trial is anticipated to pave the way for expanded use of dCellVax in a variety of other tumors. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
Regen BioPharma Submits Experimental Protocol to FDA for HemaXellerate Aplastic Anemia Trial
Marketwire - Mon Oct 06, 1:54PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today submission of a proposed experimental protocol to the FDA as part of ongoing discussions regarding initiation of a 10 patient aplastic anemia clinical trial utilizing the company's personalized adipose stem cell based therapy, HemaXellerate. The protocol submission was the result of a telephonic meeting with FDA officials, in which the Agency permitted the Company to provide additional input on preclinical safety experiments that need to be conducted before the clinical trial is initiated.
Regen BioPharma Completes Preclinical Experiments for dCellVax Breast Cancer Immune Therapy
Marketwire - Wed Oct 01, 12:46PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today completion of its preclinical experiments supporting the use of dCellVax, a personalized breast cancer immunotherapy. Animal studies, which have been previously published in peer-reviewed journals (1, 2), demonstrated that dCellVax is effective at stimulating the immune system of animals to kill tumors. In order to apply these findings to humans, proof of concept in human cells was needed.
Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
Marketwire - Tue Sep 16, 10:44AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer.
Regen BioPharma Provides Update on HemaXellerate IND Progress After Conference Call With FDA
Marketwire - Wed Sep 10, 9:01AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the outcome of a telephonic meeting with the FDA regarding IND #15376 for use of HemaXellerate in the treatment of aplastic anemia. The subject of this meeting with FDA cell therapy experts was the Company's existing experimental data and the requirement for additional safety data with regard to the IND application.
